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The aim of the study was to taste mask ciprofloxacin (CP) by using ion-exchange resins
(IERs) followed by sustain release of CP by forming interpenetrating polymer network (IPN).
IERs based on the copolymerization of acrylic acid with different cross linking agents were
synthesised. Drug-resin complexes (DRCs) with three different ratios of drug to IERs (1:1,
1:2, 1:4) were prepared & evaluated for taste masking by following in vivo and in vitro
methods. Human volunteers graded ADC 1:4, acrylic acid-divinyl benzene (ADC-3) resin as
tasteless. Characterization studies such as FTIR, SEM, DSC, P-XRD differentiated ADC 1:4,
from physical mixture (PM 1:4) and confirmed the formation of complex. In vitro drug
release of ADC 1:4 showed complete release of CP within 60 min at simulated gastric fluid
(SGF) i.e. pH 1.2. IPN beads were prepared with ADC 1:4 by using sodium alginate (AL) and
sodium alginate-chitosan (AL-CS) for sustain release of CP at SGF pH and followed by
simulated intestinal fluid (SIF i.e. pH 7.4). FTIR spectra confirmed the formation of IPN
beads. The release of CP was sustain at SGF pH (<20%) whereas in SIF media it was more
(>75%). The kinetic model of IPN beads showed the release of CP was non-Fickian diffusion
type.
© 2015 Shenyang Pharmaceutical University. Production and hosting by Elsevier B.V. This is
an open access article under the CC BY-NC-ND license (http://creativecommons.org/
licenses/by-nc-nd/4.0/).brane Division, Central Salt and Marine Chemicals Research Institute, Council of Scientific
vnagar 364 002, India. Tel.: þ91 278 2562548; fax: þ91 278 2567562.
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Ciprofloxacin (CP) has been used for the several diseases such
as infection of bones and joints, gastroenteritis and also
approved for the treatment of infections, especially urinary
tract infections, prostatitis [1]. It is a second-generation
flouroquinolone antibiotic drug having excellent tissue pene-
tration used for both oral and intravenous formulations [2,3].
Although CP has good broad spectrum antibacterial activity, it
has bitter taste which becomes palatability challenge and has
patients compliance for oral administration.
Oral administration of drug is considered to be the most
preferred route for drug delivery. Taste of an oral formulation
administered, particularly of bitter drugs, to a child or adult
has an important impact on the adherence to drug therapy.
Taste masking is an important challenge in drug delivery
since drugs dissociate in the patients mouth in close prox-
imity to the taste buds, thereby increasing the patients
compliance. A variety of methods are available for taste
masking purpose such as microencapsulation with various
polymers, coating with polymers lipids, drug resin complexes
and using lipophilic vehicles for obstructing the taste buds
[4e6]. Thesemethods are used to prevent instant drug release,
when contact with the taste bud in the oral cavity [7e9].
Among various taste masking techniques, complexation
method using ion exchange resins (IERs) is simple, cost
effective and does not require more ingredients or organic
solvents.
IERs have excellent properties like high ion-exchange ca-
pacity, good absorption capacity, physico-chemical stability
and their insolubility in any solvents make them suitable
candidates as taste masking and sustain release of drugs
[10e12]. CP has been studied for taste masking and sustain
release by some researchers. Pisal et al. studied taste masking
of CP using Indion 234 resin and also studied for sustain
release of CP at SGF pH by treating polyethylene glycol with
CP-Indion 234 complex [13,14]. Extended release tablet was
prepared by using 500 mg of CP on swellable drug poly-
electrolyte matrices by Bermudez et al. [15].
Interpenetrating polymer network (IPN) beads have been
used by many researchers for sustain release of drugs in
recent years. IPN beads proved to be a novel drug carrier as
they have many good properties [16]. They are stable,
biocompatible, non-toxic and biodegradable which have
attracted their use in pharmaceutical field. Chitosan (CS) is
environment friendly bio material, non-toxic, biodegradable,
biocompatible, hydrophilic and semi-rigid polysaccharide
which has been studied for the controlled release of drugs
in the present work. CS is derived from naturally occurring
chitin by alkaline deacetylation. CS also possesses good
mucoadhesive property and several researchers have used
CS for the entrapment of drugs [17e20]. Sodium alginate
(AL) is a polysaccharide and composed of b-D mannuronic
acid and a-D-guluronic acid polymer which can vary in
proportion and sequential distribution [21]. However, the
taste masking and sustain release of CP through synthe-
sized IERs based IPN beads using CS and AL biopolymers are
relatively new area which prompted us to study them in
details.The objective of this study was to evaluate the perfor-
mance of the synthesised resins for taste masking of CP fol-
lowed by sustain release at different pH by forming IPN beads
with AL and CS biopolymers. The IERs were prepared with
different cross linkers and also by varying crosslinking %.
These IERs have high ion exchange capacity (>11 meq/gm),
stability and insolubility properties as well as possess high
drug loading capacity.2. Materials and methods
2.1. Materials
CP was procured from Corel Pharma (p) Ltd. Ahmedabad,
India. Acrylic acid (AA), ethylene glycol dimethacrylate
(EGDMA) and N,N'-Methylenebisacrylamide (MBA) were pur-
chased from Central Drug House, Mumbai, India. Divinyl
benzene (DVB) supplied by Merck, Germany was used as
received. Benzoyl peroxide (BP) was purchased fromHeny fine
chemicals Vadodara, India. Potassium dihydrogen ortho-
phosphate, sodium hydroxide, potassium hydroxide and
other chemicals were acquired from S.D Fine Chemicals,
Mumbai, India. AL (viscosity: 20.0e40.0 CP in 1% water, MW:
7334), CS (medium molecular weight) and cellulose acetate
dialysis tube (cut off molecular mass of 12,000) were obtained
from Sigma Aldrich, USA. All other reagents used in this study
were of HPLC grade and used without further purification.
Milliporewater was used for every experiment byMillieQ plus
system (Millipore Corporation Breford, USA).2.2. Synthesis of IERs
IERs were synthesized by following suspension polymeriza-
tion technique with some modifications as reported in our
earlier work in the presence of n-heptane and isobutanol as
diluents [22]. Series of AA based IERs were prepared by
varying quantities of EGDMA, MBA and DVB. They are coded
as AEC-1, AEC-2, AEC-3, AEC-4, ABC-1, ABC-2, ABC-3 ABC-4,
ADC-1, ADC-2 and ADC-3 respectively. The details of the
synthesis of IERs are given in Table 1. IERs were conditioned
by giving alternate treatment of acid (1 N HCl) and base (1 N
NaOH) with intermittent water (Millipore water) rinsing for
three cycles and finally converted to Kþ form with KOH for
further study.
2.2.1. Preparation of drug resin complexes (DRCs)
DRCs were prepared from IERs and drug by following batch
method [23]. CP was dissolved in Millipore water and swelled
IERs were slowly added under constant stirring with a mag-
netic stirrer (Remimodel no: FHMS-3762, Mumbai, India). Each
mixturewas stirred at a speed of 500 rpmat room temperature
for 24 h. The resultant DRCs were separated by centrifugation.
The supernatant solution was filtered and set for HPLC anal-
ysis at 275 nm in order to find out loading of CP on IERs.
IERs showing comparatively higher up take of drug (i.e.
>80%) was chosen from each series to prepare DRCs by vary-
ing the ratios of AEC-1, ABC-2 and ADC-3 with CP i.e. 1:1, 1:2
and1:4 (w/w) to study their taste masking property in details.
Table 1 e Synthesis of IERs by varying ratios of monomers, cross linkers and solvents.
IERs AA (g) EGDMA (g) MBA (g) DVB (g) Heptane (g) Isobutanol (g) Crosslinking (%)
AEC-1 63 7 e e 41.6 e 10
AEC-2 72 8 e e 27.7 e 10
AEC-3 56 14 e e 41.6 e 20
AEC-4 64 16 e e 27.7 e 20
ABC-1 36 e 4 e e 60 10
ABC-2 63 e 7 e e 30 10
ABC-3 32 e 8 e e 60 20
ABC-4 54 e 16 e e 30 20
ADC-1 66.5 e e 3.5 e 30 5
ADC-2 45 e e 5 e 50 10
ADC-3 63 e e 10 e 30 10
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ABC 1:2, ABC 1:4, ADC 1:1, ADC 1:2 and ADC 1:4 respectively.
Loading of drug was calculated by following eqn.
% Loading ¼ Drug retained on IERs
Initial drug concentrat ion
 100 (1)
ADC-3 was chosen for the preparation of physicalmixtures
(PMs) with CP bymixing inmortar-pestle. They were prepared
by threedifferent ratios and codedas PM1:1, PM1:2 andPM1:4.
2.2.2. In vitro and in vivo taste masking studies
In vitro taste masking study of CP and DRCs prepared with
AEC-1, ABC-2 and ADC-3 in different ratios i.e. 1:1, 1:2 and1:4
(w/w) was carried out at simulated salivary fluid (SSF) pH 6.8.
Pre-decided amount of DRCs was dispersed in 5 ml SSF in
conical flasks separately [24]. Samples of 1mlwerewithdrawn
from the conical flask at time intervals of 30 s and filteredwith
0.45 mmWhatman filter paper. The filtrates were analysed for
CP at 275 nm by using HPLC. This study was performed in
triplicate for each sample, and the average values for respec-
tive DRCs were reported.
In vivo tastemasking study of CP, DRCs prepared with AEC-
1, ABC-2 and ADC-3 and PMs prepared with ADC-3 was per-
formed by a panel of 9 Human volunteers in the age group of
18e30 years of both the sexes fromwhomwritten consentwas
obtained after getting approval from Human Ethic Committee
(HEC no. 423/2014) of the Government Medical College, Bhav-
nagar, Gujarat. CP, different ratios DRCs prepared by CP with
AEC-1, ABC-2 and ADC-3 IERs i.e. 1:1, 1:2 and1:4 (w/w) and PMs
prepared with ADC-3 IER at ratio 1:1, 1:2 and 1:4 were placed
on tongue by each volunteer separately and taste was evalu-
ated for 30 s resident time by reportedmethod [25]. Volunteers
were asked to gargle immediately after each evaluation. The
bitterness was recorded immediately according to the bitter-
ness scale ranging from 0 to 5 (0-No Bitter, 1-Threshold Bitter,
2-Slight Bitter, 3-Moderate Bitter, 4-Bitter and 5-Strong Bitter).
The bitterness of DRCs experienced by the volunteers was
reported.
2.2.3. Powder X-ray diffraction (P-XRD)
ADC-3, CP, ADC 1:4 and PM 1:4 were investigated by Powder X-
ray diffraction (P-XRD, Phillips-X0 Pert MPD System) Nether-
land. P-XRD was recorded from 2 to 60(2q) at a scanning
speed of 0.3 deg/s. PW3123/00 curved Ni-filtered Cu-Ka
(l ¼ 1.54056 Å) radiation was used as the X-ray source.2.2.4. Fourier transforms infrared spectroscopy (FT-IR)
FT-IR was recorded on PerkineElmer, GX-FTIR, GX series
49387 (Spectrum GX, USA). The samples were mixed with KBr
and converted into pellets at 100 Kg pressure using a hydraulic
press. The spectra were obtained at the wavelength range
4000e400 cm1.
2.2.5. Scanning electron microscopy (SEM)
SEM images of dried ADC-3, CP, ADC 1:4 and PM 1:4 were
recorded by using LEO Instruments (Kowloon, Hong Kong)
microscope after the gold sputter coating on desired samples.
The samples were prepared in Millipore water and dried on
aluminium grids at room temperature prior to SEM analysis.
2.2.6. Differential scanning calorimetry (DSC)
ADC-3, CP, ADC 1:4 and PM 1:4 were assessed by DSC mea-
surements by Mettler Toledo (DSC 822e) Japan. The samples
were dried in oven for overnight at 60 C. Ten milligrams of
each sample was taken in alumina crucible and heated in the
temperature range of 30e450 C, at a 5 C/min heating rate to
assess their glass transition behaviour under nitrogen flow
(20 ml/min).
2.2.7. Preparation of ADC 1:4-AL and ADC 1:4-AL-CS IPN
beads
A known amount of ADC 1:4 containing 20 mg of CP was
mixedwith 20ml of 2% AL aqueous solution and stirred for 2 h
to get homogenous suspension. The solution was filled in
25 ml syringe having needle size 1.2 mm and poured at a
distance of 15 cm height in 0.25 M CaCl2 solution under mild
stirring at room temperature. The beads formed by ionic
gelation were cured for 30 min at room temperature followed
by washing with Millipore water and finally dried at room
temperature until constant weight was obtained.
For the synthesis ADC 1:4-AL-CS IPN beads, ADC 1:4 con-
taining 20 mg of CP was mixed with 20 ml of 2% AL solution.
Themixturewas stirred for 2 h to get homogenous suspension
solution. CS solution containing 2% was prepared separately
in acidic media at pH 4.5 under constant stirring at room
temperature and mixed in 0.25 M CaCl2 solution. The ADC 1:4
containing AL solution was dropped by using 25 ml syringe of
needle size 1.2 mm at a distance of 15 cm height with mild
stirring in the mixture containing of CS and CaCl2 solution.
The beads were cured for 30 min at room temperature fol-
lowed by washing with distilled water and finally dried at
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shows the schematic diagram for the preparation of ADC 1:4-
AL and ADC 1:4-AL-CS IPN beads by ionic crosslinking
method.
Mean diameter of dry beads was measured with micro-
meter screw (Mitutoyo, Japan) and entrapment efficiency (%)
of CP in ADC 1:4-AL and in ADC 1:4-AL-CS was determined by
HPLC at 275 nm by measuring the left CP in CaCl2 solution
during the preparation of IPN beads. The entrapment effi-
ciency was calculated by using following eqn.
% Entrapment efficiency ¼ ½ðC1 C2Þ=C1 100 (2)
where C1 is the known concentration of CP in ADC 1:4 and C2
is the concentration of CP in CaCl2 solution.
2.2.8. High pressure liquid chromatography (HPLC)
The quantitative analysis of drug (CP) was performed using
HPLC system of Waters Alliance model with Waters 2996
Photo Diode array Detector. The stationary phase was Enable
C18H (Shimadzu). The mobile phase was a mixture 0.25 M
H3PO4 and acetonitrile in the ratios of 60:40. UV detector was
set at 275 nm and oven temperature was maintained at 30 C.
The flow rate of mobile phase was 1.0 ml/min and the injec-
tion volume was 20 ml/ml. The sample temperature was
maintained at 10 C.
2.2.9. In vitro release studies
Buffer solution of pH 1.2 simulated gastric fluid (SGF) was
prepared by mixing solutions of 0.2 M HCl and 0.2 M KCl.
Buffer solution of pH 7.4 and 6.8 simulated intestinal fluid (SIF)
and simulated salivary fluid (SSF) were prepared by mixing
solutions of 0.1 M KH2PO4 and 0.1 M NaOH. In vitro release of
CP, ADC 1:4 and PM 1:4 were studied at gastric pH 1.2 by usingFig. 1 e Schematic diagram for the preparation of ADC 1:4-
AL and ADC 1:4-AL-CS IPN beads by ionic crosslinking
method.dialysis bag method. Pre-decided amount of CP, ADC 1:4 and
PM 1:4 were dispersed separately in 5 ml buffer solution in
activated cellulose dialysis bags [26]. The dialysis bags were
dipped into receptor compartment containing 100 ml of me-
dium and was shaken at 37 ± 0.5 C at a shaking speed of
100 rpm on Remi shaking water bath (Model no: RSB-12,
Mumbai, India), whereas ADC 1:4-AL and ADC 1:4-AL-CS
were studied by incubating 10 mg of CP containing IPN beads
in 100 ml of SGF (pH 1.2) in 125 ml conical flask kept in a
shaking water bath at 37 ± 0.5 C at a shaking speed of
100 rpm/min. After 3 h, the beadswere filtered and transferred
to 100 ml of SIF (pH 7.4) and incubated at 37 ± 0.5 C at a
shaking speed of 100 rpm/min. At desired intervals of time,
1 ml sample was withdrawn and replaced with same amount
of fresh medium and analysed by HPLC. Receptor compart-
ment was closed to prevent the evaporation losses from the
medium. The study was performed for three times.
2.2.10. Drug release kinetics
The drug release kinetics was performed for ADC 1:4-AL and
ADC 1:4-AL-CS IPN beads. The results obtainedwere fitted into
two kinetics models; Higuchi and Korsmeyer-Peppas. Higuchi
model describes the release of drugs as a square root of time
based on Fickian diffusion.
Q ¼ kHt1=2 (3)
kH is a constant reflecting the design variables of the sys-
tem. The release of drug from complexes was fitted by
Korsmeyer-Peppas model to find out the mechanism of drug
release by following equation [27].
Mt
M∞
¼ Ktn (4)
where Mt/M∞ is the fraction of drug released at time t, K is rate
constant and n is the diffusion exponent characteristic of
release mechanism. The n value indicates the type of release
mechanism. The values of n between 0.45 and 0.85 are due to
the diffusion controlled and swelling controlled transport
mechanism (anomalous/non-Fickian transport), the values
above 0.85 indicate case II transport mechanism (zero order)
which indicates polymer relaxation takes place during poly-
mer swelling.
2.2.11. Statistical analysis
All data are presented as mean ± standard deviation. Statis-
tical significance was assessed by using IBM SPSS statistics
version 21 software by two-way ANOVA with Duncan's mul-
tiple range test. A probability level of p < 0.05 was considered
to be statistically significant.3. Results and discussion
3.1. Drug loading on synthesized IERs
Fig. 2 shows the percentage of drug loading on all IERs. The
loading of CP was carried out to select the IERs from each
series with highest drug loading capacity and to study them in
detail for taste masking. The drug loading on IERs was found
Fig. 2 e Drug loading percentage with different IERs (A) AECs (B) ABCs (C) ADCs.
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crosslinking showed high loading of CP whereas the drug
loading is low for the IERs of high degree of crosslinking. This
trend is due to decrease in the availability of functional groups
on the IERs matrix at higher degree of crosslinking. The
loading of CP may be due to breaking of the van der Waals
forces between the drug molecules of carboxylic groups and
ion exchange reaction also takes place during the complex
formation between IERs and drug.
3.1.1. Effect of drug loading on different ratios of IERs
The loading of CP on AEC-1, ABC-2 and ADC-3 at 1:1, 1:2 and
1:4 ratios are tabulated in Table 2. Loading of CP increaseswith
the increase in the quantity of IERs and ADC-3 at 1:2 ratio
showed higher loading of CP compared to other IERs.Table 2 e Percentage of CP loading on AEC-1, ABC-2 and
ADC-3 at 1:1,1:2 and 1:4 ratios (n ¼ 3,x ¼ ±S.D).
IERs Ratios of CP: IERs
1:1 (%) 1:2 (%) 1:4 (%)
AEC-1 87.40 ± 0.43 97.28 ± 0.25 95.58 ± 0.34
ABC-2 88.08 ± 0.56 96.80 ± 0.03 94.68 ± 0.78
ADC-3 91.78 ± 0.14 98.67 ± 0.04 96.02 ± 0.223.1.2. In vivo and in vitro taste masking at SSF pH
Taste masking efficiency of CP, DRCs prepared with AEC-1,
ABC-2 and ADC-3 and PMs prepared with ADC-3 were car-
ried out by in vivo and the results are shown in Fig. 3A. The
statistical analysis showed significant suppression (P < 0.05)
for the drug. The taste masking of CP by different IERs was
observed in the following order AEC-1>ABC-2>ADC-3. Taste
evaluation by volunteers graded ADC 1:4 of ADC-3 (value 0.66
Fig. 3A) as tasteless as compared to other DRCs. The taste
masking value is found to be below 2 which signify the good
taste masking of DRCs and this has been explained by Man-
iruzzaman et al. [25].
In vitro taste masking efficiency of the DRCs prepared with
AEC-1, ABC-2 and ADC3 was studied for the release of CP at
SSF pH and the results are shown in Fig. 3B. The release of CP
from DRCs was in the following order AEC-1>ABC-2>ADC-3.
ADC 1:4 showed only 4.26 ± 0.38% of CP release for a contact
time of 30 s ultimately resulting in better taste masking. The
probable reason is that at pH 6.8, counter ions available to
exchange amine groups present in CP of ADC-3 complex are
not sufficient due the presence of crosslinked bulky and hy-
drophobic DVB group which ultimately results in slow release
of CP. Whereas faster drug release in case of AEC-1 and ABC-2
is observed as the copolymers possess aliphatic cross-linkers
such as EGDMA and MBA which may allow fast release of
drug as compared to ADC-3.
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(n ¼ 3) for 30 s. (B) In vitro taste masking at SSF pH after 30 s.
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studies
Based on in vivo and in vitro taste masking studies CP, ADC-3,
ADC 1:4 and PM 1:4 are extensively characterized to prove
the complexation of ADC 1:4 with FTIR, SEM, DSC, P-XRD and
in vitro drug release.
Fig. 4 shows the FT-IR spectrum of ADC-3, ADC 1:4, PM 1:4,
and CP. ADC-3 shows peaks at 3423 cm1, 2922 cm1 and
1676 cm1 which represent the stretching frequency of eOH
group, eC]C of aromatic ring and eC]O group of aryl acid
respectively which confirms the formation of ADC-3. CP
shows peak at 3379 cm1 which is correspond to eNH
stretching and the peaks from 2449 cm1 to 3093 cm1 are due
to dimerization of eCOOe group present in drug. The peak at
3537 cm1 is due to eOH stretching. The peak at 3379 cm1
corresponds toeNHof CP is absent in ADC 1:4, which confirmsADC 1:4 
CP
PM 1:4
1676
24493379
3537
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2922
3093
ADC-3
4000 3500 3000 2500 2000 1500 1000 500
Wave number (cm-1)
Fig. 4 e FTIR spectra for ADC-3, CP, ADC 1:4 and PM 1:4.the formation of complex by interacting secondary amine of
CP with ADC-3. The peaks at 3093 cm1 to 2449 cm1 are ab-
sent due to breaking of acid dimers during complexation. The
stretching frequency at 3531 cm1 corresponds to eOH group
of CP is also absent which signifies the complexation [13].
Spectra of PM 1:4 showed superimposition of CP on ADC-3
ensuring that there is no formation of complex.
Fig. 5A shows the SEM images of CP, ADC-3, ADC 1:4 and
PM 1:4. Rod-shape structure of pure CP is visualized and it
signifies the crystalline structure of the drug where as ADC-3
showed amorphous nature. PM 1:4 showed dense clusters
and crystals of CP are visualized on the surface of the image
which indicates that there is no formation of complex be-
tween CP and ADC-3 IER. A significant change in the mor-
phologies of ADC 1:4 is observed and found to be different
from images of CP, ADC-3 and PM 1:4 which clearly indicates
an amorphous form of CP have been formed during the
complexation of CP with ADC-3.
Fig. 5B shows the DSC studies of CP, ADC-3, ADC 1:4 and PM
1:4. ADC-3 did not show sharp peak but showed broad peak in
the range of 70 Ce146 C which represent the baseline tran-
sition of ADC-3. Similar studies for INDION 294 has been re-
ported by Thukaramji et al. [28]. CP shows two thermograms
peaks at 142 C and 286 C indicating glass transition tem-
perature (Tg) and melting point of drug respectively. The
thermograms of ADC 1:4 has shifted to lower temperature
73 C concluding the forming the amorphous nature when
complexed with drug. Whereas the endothermic melting
peaks of PM 1:4 were found close to the endothermic peak of
CP indicates that complex formation in PMs does not take
place. The resemblance in the sharpness of the peaks of PM 1:4
and CP further supports this observation.
Fig. 5C shows the P-XRD analysis of CP, ADC-3, ADC 1:4 and
PM 1:4. CP is observed to be crystalline by showing several
sharp peaks ranging from 8.33, 9.12, 11.4 8, 13.73, 15.30,
16.53, 18.90, 19.46, 20.03, 21.15, 22.61, 24.88, 25.9, 26.66,
27.11,30.48, and 35.09 2q respectively, while ADC-3 is
amorphous in nature with no peaks. The ADC 1:4 did not
showed diffraction peaks of CP concluding that physical state
of CP from crystalline form to amorphous form during the
Fig. 5 e (A) SEM images (B) DSC, (C) P-XRD of ADC-3, CP, ADC 1:4, and PM 1:4. (D) Drug release of CP, PM 1:4 and ADC 1:4 at
SGF pH 1.2 (n ¼ 3, x ¼ ±S.D).
Table 3 e Parameters for entrapment efficiency and bead
diameter of IPN beads (n ¼ 3,x ¼ ±S.D).
Parameters ADC 1:4-AL ADC 1:4-AL-CS
Entrapment efficiency (%) 91.85 ± 1.22 90.28 ± 0.85
Bead diameter (mm) 533 ± 12 932 ± 26
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ped CP is dispersed monomolecularly on ADC-3 matrix [29].
PM 1:4 retained the peaks of CP due to its crystal nature and
some diffused peaks due to ADC-3which indicate that there is
no complex formation.
Fig. 5D shows the in-vitro drug release studies for CP, ADC
1:4 and PM 1:4 at gastric pH 1.2. The release is observed to be in
the following order CP>PM 1:4>ADC 1:4. The higher release of
CP was observed from PM 1:4 compared to ADC 1:4. This may
be due to the complex formation between CP and ADC-3. The
displacement of Hþwith ADC 1:4 results in quick release of CP
in SGF media and it is within 60 min and similar result was
also reported by Pisal et al. for the release of CP from IERs [14].
3.3. Preparation and characterization of ADC 1:4-AL
and ADC 1:4-AL-CS beads
ADC 1:4 were designed for sustain release studies by forming
IPN beads with AL and CS biopolymers. IPN beads of ADC 1:4-AL and ADC 1:4-AL-CS showed spherical shape. The bead size
shown in Table 3 of ADC 1:4-AL was found to be 533 ± 12 mm
whereas it was increased up to 932 ± 26 mm for ADC 1:4-AL-CS;
this may be due to formation of ionic crosslinking between AL
of eCOOH and CS of NH3
þ with Ca2þ which ultimately resulted
in the increases of bead size. The increases in bead sizes have
also reported by previous researchers [30,31].
Fig. 6A shows the mechanism of ionic crosslinking with
Ca2þ between two polymer strands of AL and ionic interaction
between CS of NH3
þ and COOH of AL during the formation of
IPN beads [30]. The mechanism was confirmed by the FTIR
spectra.
Fig. 6 e (A) Schematic diagram for the preparation of ADC 1:4-AL and ADC 1:4-AL-CS IPN beads by ionic crosslinking
method. (B) Scheme representing IPN bead formation mechanism under the influence of Ca2þ crosslinking between the AL
and CS (C) FTIR spectra of ADC 1:4-AL and ADC 1:4-AL-CS.
Fig. 7 e Drug release profile of ADC 1:4, ADC 1:4-AL and
ADC 1:4-AL-CS at gastric pH 1.2 and at intestinal pH 7.4.
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 3 1e3 4 0338Fig. 6B shows FTIR spectra of ADC 1:4 (explained in Section
3.2), ADC 1:4-AL and ADC 1:4-AL-CS beads. In case of ADC 1:4-
AL beads, AL show asymmetric and symmetric stretching vi-
brations of carboxyl anions at 1622 cm1 and 1468 cm1
respectively. Cyclic ether bridge at 1022 cm1 is observed in
case of ADC 1:4-AL, confirms the entrapment of ADC 1:4 by AL.
In case of ADC 1:4-AL-CS, peaks are observed at 1022 cm1 and
1263 cm1 which indicate the stretching of CeOeC of CS. Peak
at 1635 cm1 shows the primary amine group of CS and the
peak of carboxyl anion is shifted from 1468 cm1 to 1419 cm1
due to ionic bonding of AL with CS.
The entrapment efficiency of ADC 1:4-AL and ADC 1:4-AL-
CS is tabulated in Table 3 and found to be 91.85 ± 1.22% and
90.28 ± 0.85% respectively which indicate that ADC 1:4 has
been well entrapped by the biopolymers matrices. The high
entrapment value indicates that during gelation ionic cross-
linking takes place between eCOOH group of AL and NH3
þ
group of CS. The other reason may be the low pH of the so-
lution causes ionic crosslinking between CS and AL [31].
3.3.1. Drug release profile
The drug release profile of ADC 1:4, ADC 1:4-AL and ADC 1:4-
AL-CS at gastric pH i.e. 1.2 is presented in Fig. 7. The release
of CP was completed within 60min for ADC 1:4 and was found
to be 92.53 ± 1.98%. In case of IPN beads of ADC 1:4-AL and
ADC 1:4-AL-CS the release of CP was studied for the initial
period of 3 h at SGF pH. The rate of drug release was slow
(<20%) for the IPN beads and it follows the following order i.e.
ADC 1:4-AL>ADC 1:4-AL-CS. In SGF pH 1.2 the Hþ was not able
to exchange with DRC-AL-CS IPN beads because there is ionic
bonding betweeneCOOH groups of AL andeNH3
þ groups of CS
which restrict the release of drug molecules from DRC-AL-CS
beads.
The release of CP from the IPN beads of ADC 1:4-AL and
ADC 1:4-AL-CS at SIF pH 7.4 was carried out for 7 h after
removing the IPN beads from SGF pH. After 10 h the release of
CP from ADC 1:4-AL and ADC 1:4-AL-CS was found to be88.44 ± 1.74% and 75.24 ± 1.53% respectively. In SIF media the
release CP from IPN beads of ADC 1:4-AL was fast compared to
the ADC 1:4-AL-CS may be due to the presence of phosphate
ions of buffer solution which have high affinity for Ca2þ and
increased the release rate of CP. The slow release of CP from
ADC 1:4-AL-CS may be due to the strengthening of IPN beads
by ionic interaction between COO groups of AL and NH3
þ
groups of CS. To demonstrate the above explanation the
schematic diagram and photographs representing the drug
release mechanism in SGF and SIF media of IPN beads (ADC
1:4-AL-CS) are shown in Fig. 8. Fig. 8A shows the schematic
Fig. 8 e Schematic diagrams and photographs representing the drug release mechanism in SGF and SIF media of IPN beads
(ADC 1:4-AL-CS) (A) Swelling of IPN beads of ionic crosslinking at pH 1.2 (B) Photographs of IPN beads at pH 1.2 after 3 h (C)
Complete degradation of ionic crosslinking at SIF pH (D) Photographs of IPN beads at pH 7.4 after 10 h.
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of IPN beads at pH 1.2 after 3 h Fig. 8C shows the complete
degradation of ionic crosslinking at SIF pH. Fig. 8D shows the
photograph of degraded IPN beads at pH 7.4 after 10 h.
3.3.2. Kinetics studies by Higuchi and Korsmeyer Peppas
model
The kinetics studies of ADC 1:4-AL and ADC 1:4-AL-CS were
carried out by using two models Higuchi and KorsmeyerTable 4 e Drug release kinetics for IPN beads.
Kinetic
models
Parameters ADC 1:4-AL ADC 1:4-AL-CS
pH 1.2 pH 7.4 pH 1.2 pH 7.4
Higuchi r2 0.9384 0.9569 0.9505 0.9015
kH 4.2900 5.5910 3.3055 6.5622
Korsmeyer
Peppas
r2 0.9462 0.9732 0.9722 0.9370
n 0.5542 0.5868 0.5648 0.7236
Kkp 0.7434 1.4917 1.1249 1.9749Peppas model. The values of correlation coefficient (r2) and
rate constants (k) are tabulated in Table 4. The diffusion
exponent ‘‘n’’ of ADC 1:4-AL and ADC 1:4-AL-CS follows
anomalous (non-fickian) diffusion in all medium. The n value
increased from the ADC 1:4-AL to ADC 1:4-AL-CS IPN beads
show the crosslinking effect between the AL and CS. This in-
dicates that mechanism depends on both diffusion and
swelling control. The r2 was near to unity and shows the best
fit to non fickian model [32].4. Conclusion
IERs with highest drug loading were studied for the taste
masking of CP. In vitro and in vivo taste masking studies
showed ADC 1:4 have good taste masking properties
compared to other DRCs. FT-IR spectra confirmed the possible
interaction between the drug and IERs. P-XRD and DSC
confirmed that drug was in amorphous state in the IERs by
forming complexes. ADC 1:4 studied for sustain release by
a s i a n j o u r n a l o f p h a rma c e u t i c a l s c i e n c e s 1 0 ( 2 0 1 5 ) 3 3 1e3 4 0340forming IPN beads with AL and CS. The CP release was very
slow in SGF media and when transferred into SIF media the
release of CP was due to the degradation of ionic crosslinking
of IPN beads. The kinetic study ofmodel showed the release of
CP depends on non Fickian diffusion.
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